Key facts
- Notable investors include Bpifrance, SATT Paris-Saclay.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Detera Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Detera Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Detera Therapeutics
Developer of transformative kidney therapies designed to treat rare kidney diseases. The company focuses on developing innovative, first-in-class therapies for severe, rare kidney diseases, aiming to reduce mortality and slow disease progression for conditions like Crescentic Glomerulonephritis in both adults and children, with lead candidate DTR8 targeting ANCA-Associated Vasculitis, enabling healthcare professionals to treat rare kidney diseases.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2024
- Website
- detera-therapeutics.com/
- Ownership
- Privately Held (backing)
Detera Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Detera Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Detera Therapeutics in its N-PORT filings yet. We sweep new filings monthly.